{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:41Z","timestamp":1793643341661,"version":"4.5.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.cmi.2023.05.004","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:45:50Z","timestamp":1683827150000},"page":"1225-1228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients"],"prefix":"10.1016","volume":"29","author":[{"given":"Philipp","family":"Koehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Prattes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Haensel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.05.004_bib1","article-title":"Evolving epidemiology of Pneumocystis pneumonia: findings from a longitudinal population-based study and a retrospective multi-center study in Germany","volume":"18","author":"Kolbrink","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cmi.2023.05.004_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fpubh.2019.00275","article-title":"Changing trends in the epidemiology and risk factors of Pneumocystis pneumonia in Spain","volume":"7","author":"Pereira-D\u00edaz","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.cmi.2023.05.004_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2023.04.015","article-title":"How to diagnose and treat a non-HIV patient with Pneumocystis jirovecii pneumonia (PCP)?","author":"H\u00e4nsel","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.05.004_bib4","year":"2020"},{"key":"10.1016\/j.cmi.2023.05.004_bib5","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkw158","article-title":"ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients","volume":"71","author":"Maschmeyer","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.05.004_bib6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1378\/chest.118.3.704","article-title":"Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2023.05.004_bib7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.05.004_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/antibiotics11060719","article-title":"Efficacy of trimethoprim-sulfamethoxazole in combination with an echinocandin as a first-line treatment option for Pneumocystis pneumonia: a systematic review and meta-analysis","volume":"11","author":"Kato","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2023.05.004_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070619","article-title":"Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice","volume":"8","author":"Lobo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2023.05.004_bib10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.05.004_bib11","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1093\/cid\/ciaa1805","article-title":"Pneumocystis jirovecii disease: basis for the revised EORTC\/MSGERC Invasive Fungal Disease Definitions in individuals without human immunodeficiency virus","volume":"72","author":"Lagrou","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.05.004_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijid.2019.08.015","article-title":"High initial (1,3) beta-d-glucan concentration may be a predictor of satisfactory response of caspofungin combined with TMP\/SMZ for HIV-negative patients with moderate to severe Pneumocystis jirovecii pneumonia","volume":"88","author":"Jin","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2023.05.004_bib13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)66516-6","article-title":"Multiplicity in randomised trials II: subgroup and interim analyses","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2023.05.004_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrmicro1621","article-title":"Current insights into the biology and pathogenesis of Pneumocystis pneumonia","volume":"5","author":"Thomas","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2023.05.004_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008524","article-title":"Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection","volume":"5","author":"Cushion","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2023.05.004_bib16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS","volume":"328","author":"Hughes","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.05.004_bib17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/0003-4819-124-9-199605010-00003","volume":"124","author":"Safrin","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2023.05.004_bib18","doi-asserted-by":"crossref","first-page":"e1252","DOI":"10.1093\/cid\/ciac386","article-title":"Treatment with reduced-dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with hematologic malignancies","volume":"76","author":"Hammarstr\u00f6m","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23002082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23002082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:35:17Z","timestamp":1761118517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23002082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1198743X23002082"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.05.004","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}